DCT

2:26-cv-09363

AbbVie Inc v. Alkem Laboratories Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-09363, D.N.J., 07/24/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Alkem, an Indian corporation, may be sued in any judicial district. Plaintiffs further allege Alkem has continuous and systematic contacts with the state through its subsidiaries, intends to sell its products in New Jersey, and has previously invoked the jurisdiction of the D.N.J. in other patent litigation.
  • Core Dispute: Plaintiffs allege that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market generic versions of Plaintiffs' LINZESS® (linaclotide) capsules constitutes an act of infringement of seven U.S. patents.
  • Technical Context: The technology relates to linaclotide, a peptide-based drug for treating chronic gastrointestinal disorders such as Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC).
  • Key Procedural History: This is a Hatch-Waxman patent infringement action initiated in response to a Paragraph IV Notice Letter from Alkem, indicating its intent to market a generic version of LINZESS® prior to the expiration of the patents-in-suit. The complaint notes that some of the asserted patents have been the subject of prior litigation against other generic pharmaceutical companies, but not against the current Defendant, Alkem. Several patents have received a 6-month Pediatric Exclusivity extension.

Case Timeline

Date Event
2003-01-28 '036, '030, and '371 Patents Priority Date
2007-12-04 U.S. Patent No. 7,304,036 Issue Date
2008-08-15 U.S. Patent No. 8,802,628 Priority Date
2009-08-06 U.S. Patent No. 8,748,573 Priority Date
2010-08-11 U.S. Patent Nos. 10,675,325 and 10,702,576 Priority Date
2012-08-30 LINZESS® Original FDA Approval
2014-06-10 U.S. Patent No. 8,748,573 Issue Date
2014-08-12 U.S. Patent No. 8,802,628 Issue Date
2015-01-13 U.S. Patent No. 8,933,030 Issue Date
2017-07-18 U.S. Patent No. 9,708,371 Issue Date
2020-06-09 U.S. Patent No. 10,675,325 Issue Date
2020-07-07 U.S. Patent No. 10,702,576 Issue Date
2023-06-01 FDA Approval for LINZESS® 72 mcg (Pediatric FC, 6-17 years)
2025-10-01 FDA grants Pediatric Exclusivity to LINZESS®
2025-11-01 FDA Approval for LINZESS® 145 mcg (Pediatric IBS-C, 7+ years)
2026-05-01 FDA Approval for LINZESS® 72 mcg (Pediatric FC, 2+ years)
2026-06-11 Alkem sends Paragraph IV Notice Letter
2026-07-24 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,304,036 - "Methods and Compositions for the Treatment of Gastrointestinal Disorders"

  • Issued: December 4, 2007

The Invention Explained

  • Problem Addressed: The patent addresses the need for effective treatments for common and debilitating gastrointestinal (GI) disorders, such as Irritable Bowel Syndrome (IBS), for which few prescription options existed at the time of invention US 7,304,036 B2, col. 1:19-48
  • The Patented Solution: The patent describes peptides that act as agonists for the guanylate cyclase C (GC-C) receptor. Activation of this receptor on intestinal epithelial cells initiates a cascade that increases intestinal fluid secretion and motility, thereby alleviating symptoms of GI disorders like constipation and pain US 7,304,036 B2, abstract US 7,304,036 B2, col. 2:11-24 The primary peptide disclosed is linaclotide.
  • Technical Importance: The invention provided a novel therapeutic mechanism for treating GI disorders by acting locally on the GC-C receptor with minimal systemic absorption, offering a targeted approach to symptom relief US 7,304,036 B2, col. 4:1-9

Key Claims at a Glance

The complaint does not identify specific claims but alleges infringement of "one or more claims" of the '036 Patent Compl. ¶52 A representative independent claim is Claim 64, a method of treatment claim, which includes the following essential elements:

  • A method for treating a gastrointestinal disorder in a patient
  • comprising administering to the patient an effective amount of a pharmaceutical composition comprising:
  • (a) a purified peptide consisting of the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; and
  • (b) a pharmaceutically acceptable carrier or excipient.

U.S. Patent No. 8,933,030 - "Treatments for Gastrointestinal Disorders"

  • Issued: January 13, 2015

The Invention Explained

  • Problem Addressed: The patent addresses the ongoing need for treatments for GI disorders such as IBS and chronic constipation US 8,933,030 B2, col. 1:24-40
  • The Patented Solution: This patent describes derivatives of linaclotide, including a ketone derivative at the N-terminal cysteine (Cys¹-a-ketone), that also function as GC-C agonists US 8,933,030 B2, col. 3:1-col. 4:14 These modified peptides may possess altered stability, activity, or pharmacokinetic properties compared to the parent linaclotide molecule.
  • Technical Importance: The invention expands the therapeutic toolkit by creating modified versions of linaclotide, potentially offering improved drug characteristics for treating GI disorders.

Key Claims at a Glance

The complaint does not identify specific claims Compl. ¶80 A representative independent claim is Claim 1, which covers a composition of matter, broken down as:

  • A peptide or a pharmaceutically acceptable salt thereof,
  • wherein the peptide comprises the amino acid structure of:
  • [A Cys¹-a-ketone derivative of linaclotide, where the N-terminal amine is replaced by a ketone group].

U.S. Patent No. 9,708,371 - "Treatments for Gastrointestinal Disorders"

  • Issued: July 18, 2017
  • Technology Synopsis: This patent, part of the same family as the '036 and '030 patents, also describes methods of treating GI disorders by administering peptides that act as GC-C agonists US 9,708,371 B2, abstract It appears to cover further modifications and derivatives of linaclotide, such as those with modified sulfur bonds (trisulfides) or other chemical alterations, aimed at providing alternative therapeutic compounds US 9,708,371 B2, col. 13:50-col. 14:38
  • Asserted Claims: The complaint does not specify which claims are asserted Compl. ¶108
  • Accused Features: Alkem's generic linaclotide ANDA products in 72 mcg, 145 mcg, and 290 mcg dosages Compl. ¶108

U.S. Patent No. 8,802,628 - "Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration"

  • Issued: August 12, 2014
  • Technology Synopsis: This patent addresses the chemical instability of linaclotide in solid formulations. The invention provides a stable formulation by combining linaclotide with a cation (such as Ca²⁺ or Mg²⁺) and a sterically hindered primary amine (such as leucine) to suppress degradation pathways like oxidation and the formation of formaldehyde imine adducts US 8,802,628 B2, col. 7:1-15
  • Asserted Claims: The complaint does not specify which claims are asserted Compl. ¶136
  • Accused Features: Alkem's generic linaclotide ANDA products in 145 mcg and 290 mcg dosages Compl. ¶136

U.S. Patent No. 8,748,573 - "Formulations Comprising Linaclotide"

  • Issued: June 10, 2014
  • Technology Synopsis: Similar to the '628 patent, this invention addresses the instability of linaclotide. It discloses stable pharmaceutical compositions containing linaclotide, a polymer (e.g., polyvinyl alcohol or polyvinyl pyrrolidone), a stabilizing amino acid (e.g., leucine), and a stabilizing cation (e.g., Ca²⁺) US 8,748,573 B2, col. 7:20-col. 8:50
  • Asserted Claims: The complaint does not specify which claims are asserted Compl. ¶165
  • Accused Features: Alkem's generic linaclotide ANDA products in 145 mcg and 290 mcg dosages Compl. ¶165

U.S. Patent No. 10,675,325 - "Stable Formulations of Linaclotide"

  • Issued: June 9, 2020
  • Technology Synopsis: This patent describes stable pharmaceutical compositions of linaclotide comprising a cation (e.g., Ca²⁺) and histidine, optionally with a polymer such as polyvinyl alcohol (PVA). The specific combination is claimed to enhance stability, particularly in low-dose formulations US 10,675,325 B2, col. 9:1-col. 10:46
  • Asserted Claims: The complaint does not specify which claims are asserted Compl. ¶192
  • Accused Features: Alkem's generic linaclotide ANDA product in the 72 mcg dosage Compl. ¶192

U.S. Patent No. 10,702,576 - "Stable Formulations of Linaclotide"

  • Issued: July 7, 2020
  • Technology Synopsis: This patent, related to the '325 patent, also claims stable linaclotide formulations. The invention covers methods of treating GI disorders by administering compositions comprising linaclotide, a cation (Ca²⁺), and histidine, which are asserted to have improved stability US 10,702,576 B2, col. 37:5-col. 38:53
  • Asserted Claims: The complaint does not specify which claims are asserted Compl. ¶220
  • Accused Features: Alkem's generic linaclotide ANDA product in the 72 mcg dosage Compl. ¶220

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are Defendant Alkem's ANDA Products, which are generic versions of LINZESS® (linaclotide) capsules in 72 mcg, 145 mcg, and 290 mcg dosage forms Compl. ¶1 Compl. ¶37

Functionality and Market Context

  • The complaint alleges that Alkem's ANDA Products are intended to be pharmaceutically and therapeutically equivalent to Plaintiffs' LINZESS® capsules Compl. ¶51 LINZESS® is described as a "groundbreaking medicine" for treating IBS-C and CIC, conditions affecting millions of people for which treatment options were previously limited Compl. ¶¶2-4 Alkem's products, upon approval, would be sold in the United States and compete directly with LINZESS® Compl. ¶18 Compl. ¶26 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or detailed infringement contentions. The following summary is based on the general allegations that Alkem's ANDA Products, by containing linaclotide and being intended for the same indications as LINZESS®, will infringe the asserted patents.

'036 Patent Infringement Allegations

Claim Element (from Independent Claim 64) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for treating a gastrointestinal disorder in a patient Alkem's ANDA Products are intended for the treatment of GI disorders, specifically IBS-C and CIC, and the product labeling will instruct this use. ¶51; ¶55 col. 2:11-24
comprising administering to the patient an effective amount of a pharmaceutical composition Alkem's ANDA Products are pharmaceutical capsule compositions intended for administration to patients. ¶51; ¶54 col. 37:37-41
comprising: (a) a purified peptide consisting of the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Alkem's ANDA Products are alleged to be therapeutically equivalent to LINZESS® and contain linaclotide, which has the claimed amino acid sequence. ¶51; ¶52 col. 23:20-25
and (b) a pharmaceutically acceptable carrier or excipient. As capsule formulations, Alkem's ANDA Products necessarily contain pharmaceutically acceptable carriers and excipients. ¶51 col. 37:37-41
  • Identified Points of Contention:
    • Scope Questions: The primary infringement questions for the method of use claim appear straightforward, assuming Alkem's product is used as labeled. The dispute will likely center on the patent's validity (e.g., obviousness) rather than non-infringement.
    • Technical Questions: A potential technical question, for which the complaint offers no detail, is whether the term "purified peptide" imposes a specific purity limitation that Alkem's product might not meet.

'030 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A peptide or a pharmaceutically acceptable salt thereof, wherein the peptide comprises the amino acid structure of: [A Cys¹-a-ketone derivative of linaclotide] The complaint alleges infringement by Alkem's ANDA products, which are described as generic linaclotide. The complaint does not specify whether this claimed ketone derivative is alleged to be present as an impurity, a metabolite, or under a different theory. ¶80 col. 9:1-19
  • Identified Points of Contention:
    • Scope Questions: The dispute does not appear to be one of claim scope but rather one of factual correspondence.
    • Technical Questions: A central evidentiary question will be whether Alkem's ANDA product contains the specific Cys¹-a-ketone derivative required by Claim 1. The complaint provides no facts to support an allegation that Alkem's generic linaclotide product contains this specific derivative.

V. Key Claim Terms for Construction

  • The Term: "purified peptide" (from '036 Patent, Claim 64)
  • Context and Importance: The definition of "purified" is critical because it could set a quantitative threshold for the amount of linaclotide relative to impurities or related substances in an accused product. Practitioners may focus on this term to determine if Alkem's generic product, with its own unique impurity profile, meets the level of purity required by the claim.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent does not explicitly define "purified" with a specific percentage, which may support an argument for a standard industry definition of purity for a pharmaceutical active ingredient rather than an unusually high level.
    • Evidence for a Narrower Interpretation: The specification describes detailed methods for synthesizing and purifying the peptides, including chromatography US 7,304,036 B2, col. 29:21-col. 30:11 A party could argue that these detailed processes imply a high degree of purity is an essential feature of the invention, thus supporting a narrower construction.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Alkem will induce and contribute to infringement. The stated basis for inducement is that Alkem's product labeling will instruct and encourage healthcare professionals and patients to use the generic product in an infringing manner, specifically for the treatment of GI disorders Compl. ¶55 Compl. ¶83 Compl. ¶111
  • Willful Infringement: Willfulness is alleged based on Alkem's purported "actual and constructive notice" of the patents-in-suit, stemming from the receipt of the Paragraph IV Notice Letter prior to filing the suit Compl. ¶58 Compl. ¶86 Compl. ¶114 The complaint alleges Alkem acted "without a reasonable basis" for believing its product would not infringe Compl. ¶59 Compl. ¶87

VII. Analyst's Conclusion: Key Questions for the Case

  • Compositional Scope: A central issue for the five asserted formulation patents will be one of compositional identity: do Alkem's specific generic formulations-including the precise identity and amounts of excipients, salts, and amino acids-fall within the scope of the various composition and formulation claims? The complaint lacks the detail from Alkem's ANDA to assess this, making it a key area for discovery and dispute.
  • Factual Presence of Derivatives: For the patents covering linaclotide derivatives (e.g., the '030 and '371 patents), a key evidentiary question will be one of factual presence: does Alkem's product, which is held out as a generic version of linaclotide, contain any of the specifically claimed derivatives (such as the Cys¹-a-ketone) in infringing amounts, either as a manufacturing impurity or as a foreseeable in-vivo metabolite?
  • Patent Validity: Given the multiple layers of patent protection covering the compound, its uses, and its formulations, a core part of the defense will likely be a challenge to the validity of the asserted claims. The key question for the court will be whether the claims of these later-issued patents are non-obvious and enabled over the prior art, including Plaintiffs' own earlier patents and publications.
Loading Complaint